{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "Katie Thomas contributed reporting.", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Praluent, first approved drug in new class of pharmaceuticals able to lower LDL cholesterol levels more effectively for some patients than statins, is likely to escalate growing controversy over rising drug prices; Sanofi and Regeneron Pharmaceuticals say list price of Praluent, about $14,600 a year, is justified but insurers are expected to put in place strict measures controlling which patients are eligible for the drug.", "type_of_material": "News", "word_count": "1294", "lead_paragraph": "The drug, Praluent, developed by Sanofi and Regeneron, is expected to become the next flashpoint in the growing controversy of escalating pharmaceutical price.", "pub_date": "2015-07-25T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "New Drug Sharply Lowers Cholesterol, but It\u2019s Costly", "print_headline": "New Drug Sharply Lowers Cholesterol, but It&#8217;s Costly "}, "snippet": "The drug, Praluent, developed by Sanofi and Regeneron, is expected to become the next flashpoint in the growing controversy of escalating pharmaceutical price.", "multimedia": [{"height": 126, "url": "images/2015/07/25/business/25drug-web/25drug-web-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/07/25/business/25drug-web/25drug-web-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/07/25/business/25drug-web/25drug-web-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/07/25/business/25drug-web/25drug-web-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/07/25/business/25drug-web/25drug-web-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/07/25/business/25drug-web/25drug-web-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/07/25/business/us-approves-drug-that-can-sharply-lower-cholesterol-levels.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Praluent (Drug)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Regeneron Pharmaceuticals Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Sanofi SA", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "5", "is_major": "Y", "value": "Cholesterol", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "55b284e038f0d839f92b9e58", "source": "The New York Times"}